COUGH is the #5 most commonly reported adverse reaction for FLUTICASONE FUROATE, manufactured by GlaxoSmithKline LLC. There are 871 FDA adverse event reports linking FLUTICASONE FUROATE to COUGH. This represents approximately 2.4% of all 35,585 adverse event reports for this drug.
Patients taking FLUTICASONE FUROATE who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COUGH871 of 35,585 reports
COUGH is a less commonly reported adverse event for FLUTICASONE FUROATE, but still significant enough to appear in the safety profile.
Other Side Effects of FLUTICASONE FUROATE
In addition to cough, the following adverse reactions have been reported for FLUTICASONE FUROATE:
COUGH has been reported as an adverse event in 871 FDA reports for FLUTICASONE FUROATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COUGH with FLUTICASONE FUROATE?
COUGH accounts for approximately 2.4% of all adverse event reports for FLUTICASONE FUROATE, making it a notable side effect.
What should I do if I experience COUGH while taking FLUTICASONE FUROATE?
If you experience cough while taking FLUTICASONE FUROATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.